The global conjugate vaccine market size was estimated at USD 19.01 billion in 2023 and is expected to grow at a CAGR of 9.60% from 2024 to 2030. The rising incidence of infectious diseases globally is a significant driver for the growth of the conjugate vaccines market. Conjugate vaccines help protect against several serious bacterial diseases, including Haemophilus influenzae disease b (Hib, Pneumococcal infections, and Meningococcal infections. According to the CDC, pneumococci, specifically Streptococcus pneumonia bacteria, are a significant cause of bacterial meningitis in the U.S. highlighted the significant health burden posed by this bacterium. As infectious diseases threaten public health, there is a growing need for effective vaccination strategies, driving the demand for conjugate vaccines.

Another crucial factor driving the conjugate vaccines market is the rising regulatory approvals for new conjugate vaccine products. The increasing number of regulatory approvals expands the market and drives innovation within the industry. Companies are encouraged to develop novel conjugate vaccines to address unmet medical needs and target emerging infectious diseases. For Instance, in June 2024, the U.S. FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine for adults, to prevent invasive and pneumococcal disease. This approval marks a significant milestone in the fight against pneumococcal infections, which can lead to serious health issues and even death, especially among high-risk groups such as the elderly and those with specific pre-existing health problems.

Gather more insights about the market drivers, restrains and growth of the Conjugate Vaccine Market

Key Conjugate Vaccine Company Insights

Some of the key players operating in the market include Sanofi, Pfizer, Inc., Merck & Co., Inc., GSK plc and Bharat Biotech. These players are using various strategies, such as new launches, forming partnerships, expanding their operations, making acquisitions, and engaging in collaborations, to enhance their presence and gain a competitive advantage over other competitors.

Recent Developments

• In March 2024, Pfizer Inc. received marketing authorization from the European Commission for its 20-valent pneumococcal conjugate vaccine, PREVENAR 20, for active immunization in infants, children, and adolescents from 6 weeks to less than 18 years of age.

• In February 2024, SK Bioscience, in collaboration with the International Vaccine Institute (IVI), has announced that its typhoid conjugate vaccine, developed through technology transferred from IVI, has been prequalified by the World Health Organization (WHO). This milestone allows the vaccine to be purchased by UN agencies, thereby enhancing the worldwide supply of TCV (Typhoid Conjugate Vaccine).

Global Conjugate Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global conjugate vaccine market report on the basis of product, brand, disease, pathogen, patient, and region

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Monovalent Conjugate Vaccine

• Multivalent Conjugate Vaccine

Brand Outlook (Revenue, USD Million, 2018 - 2030)

• Prevnar

• Synflorix

• PedvaxHIB 

• Hiberix

• ACT-HIB

• Pentacel

• Menveo

• Menactra

• MenQuadfi 

• VAXNEUVANCE 

• CAPVAXIVE 

• Others

Disease Outlook (Revenue, USD Million, 2018 - 2030)

• Pneumococcal

• Influenza

• DTP

• Meningococcal

• Typhoid

Pathogen Outlook (Revenue, USD Million, 2018 - 2030)

• Bacterial

• Viral

• Combination

Patient Outlook (Revenue, USD Million, 2018 - 2030)

• Pediatric

• Adults

Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Conjugate Vaccine Market Intelligence Study, published by Grand View Research.